+ c1 A, L, j" m( z
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: & c0 t2 m7 `$ n3 N. uEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.$ O: O6 g" p& P* t4 C: ?6 K http://www.ncbi.nlm.nih.gov/pubmed/229681845 I- X" l: n A% M# U